We have updated our full marketing presentation on Aphria. This easy to follow 18-slide pitch updates the expected per store sales change for Ontario, Canadian EBITDA expectations and assumptions on the impact of oil-based products on ASP’s. International medical sales we believe will not have a material impact over the next two fiscal years and our expectations per country are shown. Finally, we have created two tables outlining both our financial and non-financial assumptions and valuation.
You must be logged in as a 'Perspectec Institutional Equity Research' or 'Perspective on Technology' subscriber to view this content.You may also like
The streets are talking. To us. Wall Street and Bay Street that is. We normally speak with a number of instiutional investors […]
With Aphria (APH-TSX) closing at $8.53 on Friday, the stock price is now roughly 5% above our fundamental target of $8.13. We began […]
On Wednesday February 21, Aphria posted on its social media accounts that their phase 3 expansion was complete. The next step before […]
We have updated our Aphria research pitch, including the impact of COVID-19 on our forecast. We have also updated our recommendation, price […]